Pangen Biotech Stock Net Income

222110 Stock  KRW 6,110  60.00  0.97%   
PanGen Biotech fundamentals help investors to digest information that contributes to PanGen Biotech's financial success or failures. It also enables traders to predict the movement of PanGen Stock. The fundamental analysis module provides a way to measure PanGen Biotech's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to PanGen Biotech stock.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

PanGen Biotech Company Net Income Analysis

PanGen Biotech's Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.

Net Income

 = 

(Rev + Gain)

-

(Exp + Loss)

More About Net Income | All Equity Analysis

Current PanGen Biotech Net Income

    
  (3.31 B)  
Most of PanGen Biotech's fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, PanGen Biotech is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
Competition

Based on the recorded statements, PanGen Biotech reported net income of (3.31 Billion). This is 1069.96% lower than that of the Healthcare sector and significantly lower than that of the Biotechnology industry. The net income for all Republic of Korea stocks is significantly higher than that of the company.

PanGen Net Income Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses PanGen Biotech's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of PanGen Biotech could also be used in its relative valuation, which is a method of valuing PanGen Biotech by comparing valuation metrics of similar companies.
PanGen Biotech is currently under evaluation in net income category among its peers.

PanGen Fundamentals

About PanGen Biotech Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze PanGen Biotech's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of PanGen Biotech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of PanGen Biotech based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Pair Trading with PanGen Biotech

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if PanGen Biotech position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in PanGen Biotech will appreciate offsetting losses from the drop in the long position's value.

Moving against PanGen Stock

  0.82235980 MedPactoPairCorr
  0.73302440 SK BiosciencePairCorr
  0.73086890 ISU AbxisPairCorr
  0.57144510 Green Cross LabPairCorr
  0.5244460 OLIPASS SplitPairCorr
The ability to find closely correlated positions to PanGen Biotech could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace PanGen Biotech when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back PanGen Biotech - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling PanGen Biotech to buy it.
The correlation of PanGen Biotech is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as PanGen Biotech moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if PanGen Biotech moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for PanGen Biotech can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Other Information on Investing in PanGen Stock

PanGen Biotech financial ratios help investors to determine whether PanGen Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in PanGen with respect to the benefits of owning PanGen Biotech security.